Business Context and Reporting Period
This Form 8-K filing by Hancock Jaffe Laboratories, Inc. (not Envveno Medical Corp) reports on events occurring between May 31, 2018, and June 4, 2018. The primary event is the completion of the Company's Initial Public Offering (IPO) and the entry into a material definitive underwriting agreement.
Key Financial Metrics and Capital Structure
- Offering Size: 1,500,000 Units (each consisting of one share of Common Stock and one Warrant).
- Public Offering Price: $5.00 per Unit.
- Gross Proceeds: $7,500,000 (excluding over-allotment).
- Net Proceeds: Approximately $5.5 million after underwriting discounts, commissions, and estimated offering expenses.
- Underwriter Purchase Price: $4.55 per Unit.
- Warrant Terms (Public): Exercise price of $6.00 per share; expire five years from issuance.
- Underwriters' Warrants: Option to purchase up to 75,000 shares at an exercise price of $6.25 per share.
- Over-Allotment Option: Underwriters granted an option to purchase an additional 225,000 Units within 45 days; not yet exercised as of the filing date.
Note: This filing does not provide revenue, profit, cash flow, margin, or debt metrics for the Company's operations.
Material Changes
The Company transitioned from a private entity to a public company through the closing of its IPO on June 4, 2018. This event resulted in a significant influx of capital and a change in the Company's capital structure through the issuance of new common stock and warrants.
Corporate Governance and Other Events
- Lock-Up Agreement: The Company, its officers, directors, and certain stockholders agreed not to sell or dispose of Common Stock for 180 days following the IPO prospectus date, subject to exceptions.
- Charter Amendments: On June 1, 2018, the Company filed an Amended and Restated Certificate of Incorporation and adopted Amended and Restated Bylaws effective immediately prior to the IPO closing.
- Underwriting Agreement: Entered into on May 31, 2018, with Network 1 Financial Securities, Inc. as the representative.
Investor Verification Checklist
- Verify the final closing date and confirmation of net proceeds received ($5.5 million estimate).
- Confirm whether the underwriters exercised the 225,000 Unit over-allotment option within the 45-day window.
- Review the Amended and Restated Certificate of Incorporation and Bylaws (Exhibits 3.1 and 3.2) for specific governance changes.
- Check subsequent filings for the Company's first quarterly financial results post-IPO to assess operational performance.
- Monitor the status of the 180-day lock-up period expiration for insider selling activity.